Wells Fargo Doesn’t Think Becton Dickinson (BDX) Is Done Skyrocketing

Wells Fargo upgraded Becton Dickinson (BDX) to Overweight, raising its price target to $242. The medical device maker reported Q4 revenue of $5.27B and adjusted EPS of $4.15, with full-year adjusted EPS at $12.70. Wells Fargo cited improved execution and prudent fiscal 2027 guidance.

Original reporting
Published Nov 9, 2026, 4:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 5:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wells Fargo Doesn’t Think Becton Dickinson (BDX) Is Done Skyrocketing — source image
Decision brief

The 30-second read

$BDXBullishMed
01

Why it matters

The upgrade could trigger buying interest and modest price appreciation.

02

Market read

Analyst upgrade provides a fresh catalyst for BDX, likely supporting short‑term upside.

03

What to watch

Potential headwinds from regulatory changes or competitive pricing pressure.

Relevance 7/10Novelty 7/10Timing: today

Background

Wells Fargo highlighted improved execution and a prudent FY2027 guidance, noting room for upside.

Company-level read

Ticker impact

$BDXBullishHigh confidence
Context

Wells Fargo upgraded Becton Dickinson to Overweight and raised its price target to $242, indicating fresh analyst optimism.

Expected impact

likely upward pressure as investors price in the new target.

Evidence & confidence

The upgrade is a primary disclosure and provides a concrete catalyst for buying pressure.

Market effects

May lift sentiment in the medical device sector as peers could be re‑rated.

Limited to U.S. markets where BDX trades.

Minor; primarily affects BDX shareholders and sector investors.

Counterpoint

The upgrade may be premature if execution improvements falter.

Key entities

  • Wells Fargo

    Upgraded BDX to Overweight and raised price target.

Related articles

$AAPLMed

New Australian Data Shed Even More Light on Tax Avoidance by Big Tech (and Others), Highlight Need for Better Disclosure in the U.S.

The Australian Taxation Office released country-by-country tax reports, revealing that Apple (25% of profits in Singapore) and Visa (62% of profits in Singapore) booked significant profits in low-tax jurisdictions. Becton Dickinson reported $266.2M pretax income in the Cayman Islands with no local employees. The data highlights discrepancies between U.S. and Australian disclosures, raising concerns about tax transparency.

$BDXMedAI 8/10

Becton, Dickinson and Company Q4 Earnings Call Highlights

Becton, Dickinson (BDX) reported Q4 earnings, with revenue growth in Interventional (7.6%) and BioPharma Systems (7%). The company expects Q1 adjusted EPS of $2.32-$2.37, with full-year margins flat. BDX plans to discuss long-term targets on Dec. 10. Free cash flow rose 42% to $2.9B, with $3.6B returned to shareholders. BDX has a $19B U.S. investment agreement, potentially easing future tariffs.

$BDXHighAI 8/10

Becton Dickinson & Co (BDX) (Q4 2026) Earnings Call Highlights: Strong Q4 Beat, $19

Becton Dickinson (BDX) reported strong Q4 2026 results but issued cautious fiscal 2027 guidance, expecting low single-digit revenue growth due to a 200 basis point Alaris headwind. Adjusted operating margins are expected to remain flat, with inflation and investments offsetting productivity gains. The company's Q1 guidance is conservative, impacted by system cutovers and the Alaris comparison. Tariff relief benefits are not included in the guidance due to uncertainty.

$BDXMedAI 8/10

Becton, Dickinson and Company Q4 2026 Earnings Call Summary

Becton, Dickinson (BD) reported Q4 2026 earnings, highlighting 27.3% adjusted EPS growth driven by revenue gains and cost savings. The company completed a life sciences spin-off, focusing on medtech. BD expects fiscal 2027 revenue growth of mid-single digits, with Q1 performance at the low end due to Alaris headwinds. Operating margins are projected to be flat. Management targets 90% free cash flow conversion and plans to return $3.6 billion to shareholders.